AP464A - Therapeutic triazine compounds and use. - Google Patents

Therapeutic triazine compounds and use. Download PDF

Info

Publication number
AP464A
AP464A APAP/P/1994/000628A AP9400628A AP464A AP 464 A AP464 A AP 464A AP 9400628 A AP9400628 A AP 9400628A AP 464 A AP464 A AP 464A
Authority
AP
ARIPO
Prior art keywords
anxiety
disorder
pharmaceutically
triazine
diamino
Prior art date
Application number
APAP/P/1994/000628A
Other languages
English (en)
Other versions
AP9400628A0 (en
Inventor
Martyn Alan Edwin Critchley
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of AP9400628A0 publication Critical patent/AP9400628A0/xx
Application granted granted Critical
Publication of AP464A publication Critical patent/AP464A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/1994/000628A 1993-03-19 1994-03-18 Therapeutic triazine compounds and use. AP464A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939305692A GB9305692D0 (en) 1993-03-19 1993-03-19 Therapeutic triazine compounds and use

Publications (2)

Publication Number Publication Date
AP9400628A0 AP9400628A0 (en) 1994-04-30
AP464A true AP464A (en) 1996-02-20

Family

ID=10732357

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1994/000628A AP464A (en) 1993-03-19 1994-03-18 Therapeutic triazine compounds and use.

Country Status (17)

Country Link
US (1) US5658905A (de)
EP (1) EP0689440B1 (de)
JP (1) JP3633618B2 (de)
AP (1) AP464A (de)
AT (1) ATE193446T1 (de)
AU (1) AU6217794A (de)
CY (1) CY2248B1 (de)
DE (1) DE69424779T2 (de)
DK (1) DK0689440T3 (de)
ES (1) ES2147232T3 (de)
GB (1) GB9305692D0 (de)
GR (1) GR3033941T3 (de)
IL (1) IL109035A0 (de)
PH (1) PH31255A (de)
PT (1) PT689440E (de)
WO (1) WO1994021261A1 (de)
ZA (1) ZA941939B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
KR100958291B1 (ko) * 2008-01-23 2010-05-19 한국과학기술연구원 Ｔ―타입 칼슘채널을 억제하여 불안 장애를 치료하는 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021121A1 (de) * 1979-06-01 1981-01-07 The Wellcome Foundation Limited 1,2,4-Triazin-Derivate, Verfahren zur Herstellung dieser Verbindungen und sie enthaltende pharmazeutische Zusammensetzungen
EP0517347A1 (de) * 1991-06-05 1992-12-09 Schering Aktiengesellschaft Neue Kombinationspräparate zur Behandlung des Morbus Parkinson, enthaltend NMDA-Antagonisten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021121A1 (de) * 1979-06-01 1981-01-07 The Wellcome Foundation Limited 1,2,4-Triazin-Derivate, Verfahren zur Herstellung dieser Verbindungen und sie enthaltende pharmazeutische Zusammensetzungen
EP0517347A1 (de) * 1991-06-05 1992-12-09 Schering Aktiengesellschaft Neue Kombinationspräparate zur Behandlung des Morbus Parkinson, enthaltend NMDA-Antagonisten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL PHARMACOL. vol. 111, Jan. 94 M.A.E. CRITCHLEY *

Also Published As

Publication number Publication date
DE69424779T2 (de) 2000-11-02
ATE193446T1 (de) 2000-06-15
IL109035A0 (en) 1994-06-24
ES2147232T3 (es) 2000-09-01
GB9305692D0 (en) 1993-05-05
EP0689440B1 (de) 2000-05-31
DE69424779D1 (de) 2000-07-06
EP0689440A1 (de) 1996-01-03
AP9400628A0 (en) 1994-04-30
GR3033941T3 (en) 2000-11-30
US5658905A (en) 1997-08-19
JP3633618B2 (ja) 2005-03-30
CY2248B1 (en) 2003-07-04
ZA941939B (en) 1995-09-18
PT689440E (pt) 2000-10-31
PH31255A (en) 1998-06-18
AU6217794A (en) 1994-10-11
JPH08507783A (ja) 1996-08-20
DK0689440T3 (da) 2000-10-30
WO1994021261A1 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
Kales et al. Rebound insomnia: a new clinical syndrome
McNamara Pharmacotherapy of the epilepsies
Baker et al. Painful and painless mutations of SCN9A and SCN11A voltage-gated sodium channels
Sammaritano et al. Effect of anticonvulsants on sleep
Cascino Nonconvulsive status epilepticus in adults and children
EP1600167A2 (de) Pyrrolidinacetamid-Derivat, allein oder kombiniert, zur Behandlung von ZNS-Störungen
AP464A (en) Therapeutic triazine compounds and use.
Stewart et al. Ketamine prevents learning impairment when administered immediately after status epilepticus onset
Bazil Sleep-related epilepsy
US5712277A (en) Use of 3,5-diamino-6-(2,3-dichlororophenyl) -1,2,4-triazine for the treatment of pain and oedema
JP2006056905A (ja) 医学的使用
Shahar et al. Effect of add-on amantadine therapy for refractory absence epilepsy
Mitler Evaluation of temazepam as a hypnotic
JP4718771B2 (ja) 本態性振戦の予防・治療剤
DE60035162T2 (de) Ein ZNS-penetrierender NK-1-Rezeptor-Antagonist in Kombination mit einem antidepressiven oder einem anxiolytischen Wirkstoff zur Behandlung von Depression und Angst
US5120739A (en) Method of treating motion sickness
Frölich, Alfred Wiater, Gerd Lehmkuhl Successful treatment of severe parasomnias with paroxetine in a 12-year-old boy
AU612140B2 (en) Prevention or interruption of panic states with an imidazobenzodiazepine
AU4279599A (en) Use of an nk-1 receptor antagonist for treating cognitive disorders
WO1999064006A1 (en) Use of a nk-1 receptor antagonist for treating psychiatric disorders
KR100268823B1 (ko) 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진을 함유하는 약물에 대한 의존성, 내성 및 역내성의 방지 또는 감소를 위한 약제제
Stenberg et al. α2-Adrenoceptors and vigilance in cats: antagonism of medetomidine sedation by atipamezole
Bhattacharya et al. Recent advances in the management of epilepsy: A review
CA2334607A1 (en) Use of a nk-1 receptor antagonist for treating sexual dysfunctions
Gozal et al. Myocardial ischemic preconditioning decreases postischemic oxygen free radical production